September 21, 2026
| Trial | DS8201-793 (DESTINY-Lung06) |
|---|---|
| Cancer Type | Lung Cancer |
| Hospital(s) | Altnagelvin Hospital |
| Information | A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Platinum-based Chemotherapy in Combination with Pembrolizumab, as First-line Therapy in Participants with Locally Advanced Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS |
| Trial Open | Yes |